Diphencyprone Induced Vitiligo: A Case Report

Document Type : Case Report

Authors

1 Associate Professor, Skin and Stem Cell Research Center, Tehran University of Medical Sciences, Tehran AND Skin Diseases and Leishmaniasis Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

2 Skin and Stem Cell Research Center AND Cancer Research Center, Cancer Institute of Iran, Tehran University of Medical Sciences, Tehran, Iran

3 Associate Professor, Skin Diseases and Leishmaniasis Research Center, Isfahan University of Medical Sciences, Isfahan, Iran; Skin and Stem Cell Research Center, Tehran University of Medical Sciences, Tehran, Iran

4 Skin and Stem Cell Research Center, Tehran University of Medical Sciences, Tehran, Iran

Abstract

Background: Diphencyprone (DCP) is a contact sensitizer used to treat dermatological disorders with an immunological origin, such as extensive alopecia areata. Vitiligo is a rare but known side effect of diphencyprone therapy formed in the treatment site or remote areas.Case Report: In this paper, we report a 37-year-old man developed alopecia totalis with loss of eyebrows and eyelashes presented some vitiligo patches on his scalp and arm distant from the location of diphencyprone application. In addition, 42-year-old woman with 25 years history of hair loss and 3 months diphencyprone application revealed some vitiligo patches on the scalp with distant to the site of application at the 6th week is reported. Considering the absence of personal and family history of vitiligo in our two cases, the hypothesis of latent vitiligo was not proved. The positive patch test in left arm of one of the patients also suggested the direct role of diphencyprone as the cause of vitiligo occurrence.Conclusion:  As the development of vitiligo by diphencyprone is unpredictable and the depigmentation may persist indefinitely, it is important to inform all patients about this potential adverse effect before starting the treatment.

Keywords

References

  1. Gilhar A, Paus R, Kalish RS. Lymphocytes, neuropeptides, and genes involved in alopecia areata. J Clin Invest 2007; 117(8): 2019–27.
  2. Safavi KH, Muller SA, Suman VJ, Moshell AN, Melton LJ, III. Incidence of alopecia areata in Olmsted County, Minnesota, 1975 through 1989. Mayo Clin Proc 1995; 70(7): 628-33.
  3. Avgerinou G, Gregoriou S, Rigopoulos D, Stratigos A, Kalogeromitros D, Katsambas A. Alopecia areata: topical immunotherapy treatment with diphencyprone. J Eur Acad Dermatol Venereol 2008; 22(3): 320-3.
  4. Garg S, Messenger AG. Alopecia areata: evidence-based treatments. Semin Cutan Med Surg 2009; 28(1): 15-8.
  5. Ganzetti G, Simonetti O, Campanati A, Giuliodori K, Offidani A. Phototherapy as a useful therapeutic option in the treatment of diphenylcyclopropenone-induced vitiligo. Acta Derm Venereol 2010; 90(6): 642-3.
  6. Shapiro J, Madani S. Alopecia areata: diagnosis and management. Int J Dermatol 1999; 38(Suppl 1): 19-24.
  7. Cotellessa C, Peris K, Caracciolo E, Mordenti C, Chimenti S. The use of topical diphenylcyclopropenone for the treatment of extensive alopecia areata. J Am Acad Dermatol 2001; 44(1): 73-6.
  8. Hunter N, Shaker O, Marei N. Diphencyprone and topical tacrolimus as two topical immunotherapeutic modalities. Are they effective in the treatment of alopecia areata among Egyptian patients? A study using CD4, CD8 and MHC II as markers. J Dermatolog Treat 2011; 22(1): 2-10.
  9. Perret C, Wiesner-Menzel L, Happle R. Immunohistochemical analysis of T-cell subsets in the peribulbar and intrabulbar infiltrates of alopecia areata. Acta Derm Venereol 1984; 64(1): 26-30.
  10. Duhra P, Foulds IS. Persistent vitiligo induced by diphencyprone. Br J Dermatol 1990; 123(3): 415-6.
  11. Henderson CA, Ilchyshyn A. Vitiligo complicating diphencyprone sensitization therapy for alopecia universalis. Br J Dermatol 1995; 133(3): 496-7.
  12. Yadav S, Dogra S, Kaur I. An unusual anatomical colocalization of alopecia areata and vitiligo in a child, and improvement during treatment with topical prostaglandin E2. Clin Exp Dermatol 2009; 34(8): e1010-e1011.
  13. Adams BB, Lucky AW. Colocalization of alopecia areata and vitiligo. Pediatr Dermatol 1999; 16(5): 364-6.
  14. Dhar S, Kanwar AJ. Colocalization of vitiligo and alopecia areata. Pediatr Dermatol 1994; 11(1): 85-6.
  15. Pires MC, Martins JM, Montealegre F, Gatti FR. Vitiligo after diphencyprone for alopecia areata. Dermatol Res Pract 2010; 2010: 171265.
Journal of Isfahan Medical School
Volume 31, Issue 269 - Serial Number 269
November and December 2014
Pages 2346-2351

Files

History

  • Receive Date: 25 December 2012
  • Revise Date: 28 May 2024
  • Accept Date: 06 April 2022

Share

How to cite

Statistics